Populations of cisco Coregonus artedi in the Laurentian Great Lakes supported large‐scale commercial fisheries and were the primary forage of piscivores during the first half of the 20th century. However, by 1970 populations had collapsed in all of the lakes. Since then, ciscoes have staged a recovery in Lake Superior. In this synthesis, we describe the status of ciscoes in Lake Superior during 1970–2006 and provide a comprehensive review of their ecology. Better understanding of age estimation techniques, application of hydroacoustic and midwater trawl sampling, and compilation of long‐term data sets have advanced our understanding of the species. Management agencies contemplating rehabilitation of cisco populations should recognize that (1) knowledge of cisco ecology and population dynamics is increasing; (2) ciscoes are long‐lived; (3) Great Lakes populations are probably composed of both shallow‐water and deepwater spawning forms; (4) large year‐classes can be produced from small adult stocks; (5) large variation in year‐class strength is probably intrinsic to Great Lakes populations; (6) despite the longevity and early maturity of ciscoes, stocks can be overfished because large year‐classes are produced infrequently; (7) regional environmental factors appear to play a large role in reproductive success; and (8) rainbow smelt Osmerus mordax are likely to have a negative effect on cisco recruitment under certain conditions. A top‐down approach for rehabilitating lake trout Salvelinus namaycush in Lake Superior probably benefited cisco recovery through lake trout predation on invasive rainbow smelt populations. We argue that managing for populations of exotic alewives Alosa pseudoharengus to support popular recreational fisheries of exotic Pacific salmonids in the other Great Lakes conflicts with stocking efforts to rehabilitate native lake trout in those lakes. If native fish rehabilitation is a serious and primary goal for management agencies in the Great Lakes basin, we propose that an ecosystem‐based approach to modifying the environment for the benefit of native fish species (i.e., decimation or eradication of invasive species) is required.
Histamine-stimulated gastric acid secretion can be antagonized in animals [i] and in man [2] by burimamide given intravenously. This effect appears to be related to the specific blockade of histamine H2-receptors by burimamide which was demonstrated on certain tissues in vitro [1]. Potential clinical interest was aroused by the finding that burimamide also inhibited gastric acid secretion evoked by pentagastrin or gastrin. However, because of difficulties found in studying the oral effectiveness of burimamide in experimental animals, no proposal for its clinical evaluation was made. A new compound, metiamide, has now been developed which has properties suitable for evaluation of the therapeutic potential of histamine H2-receptor blockade in man, namely, high specific activity, low toxicity and good oral bioavailability. methylene group (-CH2-) with an isosteric thios ether (-S-) link in the side chain and by the addition of a methyl group in the imidazole ring. These changes alter the electron densities of the ring nitrogens and were introduced to make the preferred tautomer of the imidazole ring similar to that found in histamine in solution. These changes also alter the ionisation and lipid solubility of the compound and hence may influence its absorption from the intestine. Thus the pKa for metiamide of 6.8 implies that when the pH is below 4 in the stomach almost all the molecules will be charged due to protonation of the imidazole ring but when the pH approaches neutrality in the small intestine about half of the molecules will now be uncharged. Since uncharged molecules are much more lipid soluble than charged ones the lipid solubility ofmetiamide at pH 7 is over 40 times greater than at pH 4. Chemistry of metiamideThe molecular weight of metiamide is 244.4. Therefore doses expressed in this paper as
Celiac disease is an autoimmune gastrointestinal disorder characterized by mucosal atrophy of the jejunum on exposure to gluten, a protein found in grains. The purpose of our study was to determine the prevalence of celiac disease in children with Downs syndrome in a U.S.-based Caucasian population. The 97 Downs syndrome children were screened for celiac disease using serum IgA-anti-endomysial antibody testing, which is highly specific and sensitive for the disorder. Children with titers greater than 1:5 (using the IgA endomysial antibody [EMA] test; EMA+) were considered affected. Ten children (10.3%) were EMA+. We examined their HLA DQA1 DQB1 genotype, karyotype, clinical characteristics, and the prevalence of celiac disease in their first-degree relatives. The nine available karyotypes were trisomy 21. Downs syndrome-specific mean height percentile was 64%+/-26% (range <5-99%) and weight percentile was 43%+/-28% (range 5-95%). Presence of diarrhea, constipation, vomiting, and abdominal pain was similar for children with and without celiac disease. Only bloating symptoms were significantly more frequent in those with celiac disease (EMA+). Seven of eight (88%) genotyped EMA+ children had the celiac disease-associated high-risk HLA DQA1*0501 DQB1*0201 genotype as compared with 13/ 80 (16%) of EMA- children. Five of 48 (10%) first-degree relatives of the celiac disease (EMA+) children were EMA+. In conclusion, celiac disease, as diagnosed by positive endomysial antibody tests, has an increased prevalence in children with Downs syndrome in the U.S. as compared with the general population (1/250). Clinical and growth characteristics do not distinguish between children with and without celiac disease. Based on these observations, it is recommended that children with Downs syndrome be screened for celiac disease.
Systematic underestimation of fish age can impede understanding of recruitment variability and adaptive strategies (like longevity) and can bias estimates of survivorship. We suspected that previous estimates of annual survival (S; range = 0.20‐0.44) for Lake Superior ciscoes Coregonus artedi developed from scale ages were biased low. To test this hypothesis, we estimated the total instantaneous mortality rate of adult ciscoes from the Thunder Bay, Ontario, stock by use of cohort‐based catch curves developed from commercial gill‐net catches and otolith‐aged fish. Mean S based on otolith ages was greater for adult females (0.80) than for adult males (0.75), but these differences were not significant. Applying the results of a study of agreement between scale and otolith ages, we modeled a scale age for each otolith‐aged fish to reconstruct catch curves. Using modeled scale ages, estimates of S (0.42 for females, 0.36 for males) were comparable with those reported in past studies. We conducted a November 2005 acoustic and midwater trawl survey to estimate the abundance of ciscoes when the fish were being harvested for roe. Estimated exploitation rates were 0.085 for females and 0.025 for males, and the instantaneous rates of fishing mortality were 0.089 for females and 0.025 for males. The instantaneous rates of natural mortality were 0.131 and 0.265 for females and males, respectively. Using otolith ages, we found that strong year‐classes at large during November 2005 were caught in high numbers as age‐1 fish in previous annual bottom trawl surveys, whereas weak or absent year‐classes were not. For decades, large‐scale fisheries on the Great Lakes were allowed to operate because ciscoes were assumed to be short lived and to have regular recruitment. We postulate that the collapse of these fisheries was linked in part to a misunderstanding of cisco biology driven by scale‐ageing error.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.